{"id":"NCT03694353","sponsor":"BioMarin Pharmaceutical","briefTitle":"Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU","officialTitle":"An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/Day Dose) in Adults With Phenylketonuria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-13","primaryCompletion":"2021-01-13","completion":"2021-01-13","firstPosted":"2018-10-03","resultsPosted":"2022-02-17","lastUpdate":"2022-02-17"},"enrollment":37,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Phenylketonuria (PKU)"],"interventions":[{"type":"DRUG","name":"Pegvaliase","otherNames":["rAvPAL-PEG"]}],"arms":[{"label":"Pegvaliase","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3 open-label extension study enrolling adult patients with PKU who were previously treated with pegvaliase in Studies PAL-003 (NCT00924703) or 165-302 (NCT02468570). The study is designed to evaluate the long-term safety and efficacy of pegvaliase administered at doses \\> 40 mg/day to 60 mg/day.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0","timeFrame":"Up to Day 741 (approximately Week 106)","effectByArm":[{"arm":"All Subjects","deltaMin":36,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":37},"commonTop":["Nasopharyngitis","Headache","Influenza","Oropharyngeal pain","Amino acid level decreased"]}}